Physician profile
Tracy Collins
NPI 1720088818
$4,638.34
in general payments reported to CMS, 2019-2025
36 companies · $847 in 2025
The $847 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $65.59 · 2021: $339 · 2022: $970 · 2023: $1,391 · 2024: $435 · 2025: $847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,323 · Travel and Lodging: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,323.07 |
| Travel and Lodging | $350.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $873.80 | 2019-2023 | Acessa Provu System |
| Mayne Pharma Commercial LLC | $597.21 | 2022-2025 | |
| Abbvie INC. | $515.98 | 2019-2022 | |
| Astellas Pharma US INC | $352.08 | 2022-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $231.61 | 2019-2024 | |
| Coopersurgical, INC. | $231.16 | 2019-2025 | Paragard T 380a, Wallach Cryosurgical Equipment |
| Organon LLC | $208.51 | 2022-2025 | Nexplanon, Jada System |
| Bayer Healthcare Pharmaceuticals INC. | $182.52 | 2019-2025 | |
| Avion Pharmaceuticals | $146.43 | 2019-2023 | Balcoltra |
| Exact Sciences Corporation | $134.90 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Exeltis, USA INC. | $123.97 | 2022-2025 | Slynd |
| Shield Therapeutics INC | $111.69 | 2023-2024 | Accrufer |
| Myriad Women'S Health, INC. | $102.23 | 2023 | Myrisk |
| Sumitomo Pharma America, INC. | $101.57 | 2023-2025 | Myfembree |
| Novo Nordisk INC | $82.59 | 2022-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $64.45 | 2022 | |
| Therapeuticsmd, INC. | $63.73 | 2019-2021 | |
| Biogen, INC. | $61.72 | 2025 | Zurzuvae |
| Baxter Healthcare | $52.22 | 2021-2025 | Perclot |
| Ethicon US, LLC | $51.39 | 2019-2025 | Ethicon, Vistaseal |
| Medtronic, INC. | $42.27 | 2021 | |
| Meditrina | $35.25 | 2022-2025 | |
| Amag Pharmaceuticals, INC. | $33.74 | 2019 | |
| Mylan Pharmaceuticals INC. | $24.90 | 2021 | |
| Innovation Technologies INC | $24.24 | 2024 | Irrisept |
| Allergan, INC. | $24.07 | 2019 | |
| Seqirus USA INC | $23.41 | 2025 | Fluad, Flucelvax |
| Merck Sharp & Dohme LLC | $19.20 | 2019 | |
| Mallinckrodt Enterprises LLC | $18.29 | 2019 | |
| Myovant Sciences INC. | $18.02 | 2021 | |
| Gynesonics, INC. | $17.50 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Teleflex LLC | $16.36 | 2022 | |
| Monaghan Medical Corporation | $13.44 | 2023 | Aeroeclipse |
| Vertical Pharmaceuticals, LLC | $13.13 | 2019 | |
| Minerva Surgical, INC | $13.08 | 2019 | |
| Daiichi Sankyo INC. | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.